Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
07/2010
07/01/2010US20100168396 Novel Branchiostoma Derived Fluorescent Proteins
07/01/2010US20100168391 Pegylated Factor VIII
07/01/2010US20100168390 Mhc multimers, methods for their generation, labeling and use
07/01/2010US20100168389 Process for producing extract for cell-free protein synthesis and cell extract produced thereby
07/01/2010US20100168388 Stabilized p53 peptides and uses thereof
07/01/2010US20100168387 Chimeric CrylE Delta Endotoxin and Methods of Controlling Insects
07/01/2010US20100168386 Fusion protein carrying neurotrophin across the blood-brain barrier, encoding gene and uses thereof
07/01/2010US20100168382 Neuroplastin derived peptides
07/01/2010US20100168381 Conjugates of membrane translocating agents and pharmaceutically active agents
07/01/2010US20100168214 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
07/01/2010US20100168031 Lat peptides and their use in assays for identifying immunosuppressants
07/01/2010US20100168028 Compositions and methods of using crmp-1 and its fragments for treating cancer
07/01/2010US20100168027 Bpc-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells
07/01/2010US20100168026 Insulin secretion inducer, and accelerator for increasing the number of pancreatic beta-cells
07/01/2010US20100168021 Urocortin proteins and uses thereof
07/01/2010US20100168020 Stabilized receptor polypeptides and uses thereof
07/01/2010US20100168019 Peptide conjugated anti-cancer prodrugs
07/01/2010US20100168015 Peptides with capacity for binding with interleukine 10 (il-10)
07/01/2010US20100168014 Screening method
07/01/2010US20100168009 PHa1B TOXIN, cDNA of Pha1B TOXIN GENE, PHARMACEUTICAL COMPOSITION CONTAINING PHa1B TOXIN, PROCESS AND PRODUCT
07/01/2010US20100168006 In-plant production of dimeric and/or oligomeric (comprising three or more units) forms of human apo a-1 protein muteins
07/01/2010US20100168002 Therapeutic peptides
07/01/2010US20100168001 Method for Preventing and/or Treating Articles or Media Contaminated With Bacteria of the Legionelle Genus
07/01/2010US20100168000 Octanoate-Reduced Human Albumin
07/01/2010US20100167984 Complex between human insulin and an amphiphilic polymer and use of this complex in the preparation of a fast-acting human insulin formulation
07/01/2010US20100167418 Stabilized low affinity conformation of integrins for drug discovery
07/01/2010US20100167417 Long wavelength thiol-reactive fluorophores
07/01/2010US20100167411 Novel slc17-type transporter protein in mammal and use thereof
07/01/2010US20100167394 Ultramarine fluorescent protein
07/01/2010US20100167393 Modified human thymic stromal lymphopoietin
07/01/2010US20100167392 Factor viii compositions and methods
07/01/2010US20100167391 Growth factor homolog zvegf3
07/01/2010US20100167375 Novel Lipolytic Enzyme LIP2
07/01/2010US20100167374 Ultra-fast chromatography
07/01/2010US20100167352 Infectious clones
07/01/2010US20100167348 Peptide capable of binding to immunoglobulin
07/01/2010US20100167333 Heavy Metal Binding Compounds and Their Method of Use
07/01/2010US20100167327 System for obfuscating identity
07/01/2010US20100167321 Epitope/peptide recognized by hla-a2402-restricted ep-cam-specific ctl and use of the same
07/01/2010US20100167314 Control of intracellular target molecule by ip3 receptor-binding protein
07/01/2010US20100167290 Molecule attachment to nanoparticles
07/01/2010US20100167275 Potassium channel mutants of the yeast Saccharomyces cerevisiae and their use for screening eukaryotic potassium channels
07/01/2010US20100167265 Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of hiv infections, antibodies and method of diagnosis
07/01/2010US20100166800 Recombinant attenuated clostridium organisms and vaccine
07/01/2010US20100166794 Plasmodium liver stage antigens
07/01/2010US20100166793 Protease-resistant modified seb and vaccine containing the same
07/01/2010US20100166792 Antigenic Polypeptides
07/01/2010US20100166791 Circovirus sequences associated with piglet weight loss disease (pwd)
07/01/2010US20100166790 Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris)
07/01/2010US20100166789 Proteins for use in diagnosing and treating infection and disease
07/01/2010US20100166788 Immunogens from uropathogenic escherichia coli
07/01/2010US20100166787 Vaccines and methods for using the same
07/01/2010US20100166786 A mycobacterium tuberculosis fusion protein and uses thereof
07/01/2010US20100166777 Hematopoietic cells that express mosc-1
07/01/2010US20100166772 ANTIGEN-BINDING PROTEINS TARGETING S. AUREUS ORF0657n
07/01/2010US20100166771 detecting NTHi bacteria in a biological sample using a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 599; vaccines and methods of treating and preventing NTHi related disorders such as NTHi infection of the middle ear and/or the nasopharynx
07/01/2010US20100166761 Compositions and methods for the treatment of immune related diseases
07/01/2010US20100166759 Metallothionein-Derived Peptide Fragments
07/01/2010US20100166756 Method for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
07/01/2010US20100166732 Small streptococcus pyogenes antigens and their use
07/01/2010US20100166702 Alkylated interleukin-18 and related compositions, kits, and methods of making and using same
07/01/2010US20100166700 Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation
07/01/2010US20100166658 Monkey homolog of human oncostatin m
07/01/2010DE112008001326T5 Pflanzen mit verbesserten Ertragsmerkmalen und Verfahren zu ihrer Herstellung Plants having enhanced yield characteristics and methods for their preparation
07/01/2010CA2748308A1 Hnrnp a3 related peptides and use thereof for diagnosis of rheumatoid arthritis
07/01/2010CA2748180A1 Oncolytic adenoviral vectors and methods and uses related thereto
07/01/2010CA2748149A1 Modified steptococcus pneumonia pneumolysin (ply) polypeptides
07/01/2010CA2748015A1 Protein substance having triple helix structure and manufacturing method therefor
07/01/2010CA2748009A1 Compositions and methods for re-programming cells without genetic modification
07/01/2010CA2747826A1 Axmi-150 delta-endotoxin gene and methods for its use
07/01/2010CA2747812A1 Pesticidal genes from brevibacillus and methods for their use
07/01/2010CA2747686A1 C1orf59 peptides and vaccines including the same
07/01/2010CA2746892A1 Tor-interacting proteins (tips) and genes therefor
07/01/2010CA2746858A1 Human cgrp receptor binding proteins
07/01/2010CA2746330A1 Immunoglobulin variants with altered binding to protein a
07/01/2010CA2745557A1 Process for the preparation of a peptide powder form
07/01/2010CA2745371A1 Methods, reagents and kits for the identification of modulators of voltage-gated sodium channels
07/01/2010CA2738989A1 Efficient transport into white blood cells
07/01/2010CA2738951A1 Novel transporter constructs and transporter cargo conjugate molecules
06/2010
06/30/2010EP2202315A1 Modified vaccinia ankara virus variant
06/30/2010EP2202310A2 Caustic stable chromatography ligands
06/30/2010EP2202308A2 Methods and compositions for polypeptide engineering
06/30/2010EP2202298A1 Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV
06/30/2010EP2202297A1 Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
06/30/2010EP2202295A1 Method for efficient production of monocyte-derived multipotent cell (momc)
06/30/2010EP2202242A1 Inactivation resistant factor VIII related applications
06/30/2010EP2202241A2 Therapeutic compounds and methods for modulating V3, a versican isoform
06/30/2010EP2201960A1 Conformationally constrained parathyroid hormones with alpha-helix stabilizers
06/30/2010EP2201959A2 Use of IL-12 and IL-12 antagonists for the manufacture of a pharmaceutical composition for the treatment of autoimmune diseases
06/30/2010EP2201377A1 Purinergic (p2x) receptors in extra-cellular body fluid
06/30/2010EP2201376A1 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies
06/30/2010EP2201121A1 Methods of controlling plant seed and organ size
06/30/2010EP2201119A2 Advanced cervical cell screening methods
06/30/2010EP2201035A1 Novel avian cytokines and genetic sequences encoding same
06/30/2010EP2201034A1 Neuroprotection using nap-like and sal-like peptide mimetics
06/30/2010EP2201033A2 Methods of treating cancer using notch pathway inhibitors
06/30/2010EP2201032A1 Maintenance of hair growth and treatment of hair-loss
06/30/2010EP2201031A1 Hypoallergenic variants of the major allergen from betula verrucosa pollen
06/30/2010EP2201030A2 Axmi-066 and axmi-076: delta-endotoxin proteins and methods for their use
06/30/2010EP2201029A1 Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof